nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Teniposide—lymphatic system cancer	0.107	0.367	CbGbCtD
Paliperidone—CYP3A5—Vincristine—lymphatic system cancer	0.0516	0.176	CbGbCtD
Paliperidone—CYP3A4—Cytarabine—lymphatic system cancer	0.0424	0.145	CbGbCtD
Paliperidone—CYP3A4—Teniposide—lymphatic system cancer	0.0418	0.143	CbGbCtD
Paliperidone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0292	0.1	CbGbCtD
Paliperidone—CYP3A4—Vincristine—lymphatic system cancer	0.0201	0.0688	CbGbCtD
Paliperidone—Diarrhoea—Teniposide—lymphatic system cancer	0.001	0.00142	CcSEcCtD
Paliperidone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.001	0.00141	CcSEcCtD
Paliperidone—Chest pain—Bleomycin—lymphatic system cancer	0.000987	0.00139	CcSEcCtD
Paliperidone—Myalgia—Bleomycin—lymphatic system cancer	0.000987	0.00139	CcSEcCtD
Paliperidone—Alopecia—Vincristine—lymphatic system cancer	0.00098	0.00139	CcSEcCtD
Paliperidone—Back pain—Carmustine—lymphatic system cancer	0.000979	0.00138	CcSEcCtD
Paliperidone—Discomfort—Bleomycin—lymphatic system cancer	0.000975	0.00138	CcSEcCtD
Paliperidone—Mental disorder—Vincristine—lymphatic system cancer	0.000972	0.00137	CcSEcCtD
Paliperidone—Chills—Mitoxantrone—lymphatic system cancer	0.000969	0.00137	CcSEcCtD
Paliperidone—Bladder pain—Methotrexate—lymphatic system cancer	0.000969	0.00137	CcSEcCtD
Paliperidone—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000959	0.00136	CcSEcCtD
Paliperidone—Alopecia—Mitoxantrone—lymphatic system cancer	0.000955	0.00135	CcSEcCtD
Paliperidone—Confusional state—Bleomycin—lymphatic system cancer	0.000954	0.00135	CcSEcCtD
Paliperidone—Vision blurred—Carmustine—lymphatic system cancer	0.000953	0.00135	CcSEcCtD
Paliperidone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00095	0.00134	CcSEcCtD
Paliperidone—Tremor—Carmustine—lymphatic system cancer	0.000948	0.00134	CcSEcCtD
Paliperidone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000946	0.00134	CcSEcCtD
Paliperidone—Oedema—Bleomycin—lymphatic system cancer	0.000946	0.00134	CcSEcCtD
Paliperidone—Erythema—Mitoxantrone—lymphatic system cancer	0.00094	0.00133	CcSEcCtD
Paliperidone—Infection—Bleomycin—lymphatic system cancer	0.00094	0.00133	CcSEcCtD
Paliperidone—Anaemia—Carmustine—lymphatic system cancer	0.000935	0.00132	CcSEcCtD
Paliperidone—Back pain—Vincristine—lymphatic system cancer	0.000934	0.00132	CcSEcCtD
Paliperidone—Vomiting—Teniposide—lymphatic system cancer	0.000933	0.00132	CcSEcCtD
Paliperidone—Agitation—Carmustine—lymphatic system cancer	0.00093	0.00131	CcSEcCtD
Paliperidone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000926	0.00131	CcSEcCtD
Paliperidone—Asthenia—Fludarabine—lymphatic system cancer	0.000926	0.00131	CcSEcCtD
Paliperidone—Rash—Teniposide—lymphatic system cancer	0.000925	0.00131	CcSEcCtD
Paliperidone—Dermatitis—Teniposide—lymphatic system cancer	0.000925	0.00131	CcSEcCtD
Paliperidone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000921	0.0013	CcSEcCtD
Paliperidone—Headache—Teniposide—lymphatic system cancer	0.00092	0.0013	CcSEcCtD
Paliperidone—Pruritus—Fludarabine—lymphatic system cancer	0.000913	0.00129	CcSEcCtD
Paliperidone—Back pain—Mitoxantrone—lymphatic system cancer	0.00091	0.00129	CcSEcCtD
Paliperidone—Leukopenia—Carmustine—lymphatic system cancer	0.000906	0.00128	CcSEcCtD
Paliperidone—Anorexia—Bleomycin—lymphatic system cancer	0.000902	0.00127	CcSEcCtD
Paliperidone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000895	0.00126	CcSEcCtD
Paliperidone—Anaemia—Vincristine—lymphatic system cancer	0.000893	0.00126	CcSEcCtD
Paliperidone—Agitation—Vincristine—lymphatic system cancer	0.000887	0.00125	CcSEcCtD
Paliperidone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000886	0.00125	CcSEcCtD
Paliperidone—Hypotension—Bleomycin—lymphatic system cancer	0.000884	0.00125	CcSEcCtD
Paliperidone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000883	0.00125	CcSEcCtD
Paliperidone—Convulsion—Carmustine—lymphatic system cancer	0.000876	0.00124	CcSEcCtD
Paliperidone—Hypertension—Carmustine—lymphatic system cancer	0.000873	0.00123	CcSEcCtD
Paliperidone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000873	0.00123	CcSEcCtD
Paliperidone—Nausea—Teniposide—lymphatic system cancer	0.000872	0.00123	CcSEcCtD
Paliperidone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000869	0.00123	CcSEcCtD
Paliperidone—Vertigo—Vincristine—lymphatic system cancer	0.000868	0.00123	CcSEcCtD
Paliperidone—Leukopenia—Vincristine—lymphatic system cancer	0.000864	0.00122	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000862	0.00122	CcSEcCtD
Paliperidone—Myalgia—Carmustine—lymphatic system cancer	0.000861	0.00122	CcSEcCtD
Paliperidone—Chest pain—Carmustine—lymphatic system cancer	0.000861	0.00122	CcSEcCtD
Paliperidone—Anxiety—Carmustine—lymphatic system cancer	0.000858	0.00121	CcSEcCtD
Paliperidone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000849	0.0012	CcSEcCtD
Paliperidone—Malaise—Mitoxantrone—lymphatic system cancer	0.000848	0.0012	CcSEcCtD
Paliperidone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000843	0.00119	CcSEcCtD
Paliperidone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000842	0.00119	CcSEcCtD
Paliperidone—Convulsion—Vincristine—lymphatic system cancer	0.000837	0.00118	CcSEcCtD
Paliperidone—Hypertension—Vincristine—lymphatic system cancer	0.000834	0.00118	CcSEcCtD
Paliperidone—Confusional state—Carmustine—lymphatic system cancer	0.000832	0.00118	CcSEcCtD
Paliperidone—Oedema—Carmustine—lymphatic system cancer	0.000826	0.00117	CcSEcCtD
Paliperidone—Decreased appetite—Bleomycin—lymphatic system cancer	0.000822	0.00116	CcSEcCtD
Paliperidone—Myalgia—Vincristine—lymphatic system cancer	0.000822	0.00116	CcSEcCtD
Paliperidone—Cough—Mitoxantrone—lymphatic system cancer	0.000821	0.00116	CcSEcCtD
Paliperidone—Infection—Carmustine—lymphatic system cancer	0.00082	0.00116	CcSEcCtD
Paliperidone—Vomiting—Fludarabine—lymphatic system cancer	0.00082	0.00116	CcSEcCtD
Paliperidone—Convulsion—Mitoxantrone—lymphatic system cancer	0.000815	0.00115	CcSEcCtD
Paliperidone—Rash—Fludarabine—lymphatic system cancer	0.000813	0.00115	CcSEcCtD
Paliperidone—Dermatitis—Fludarabine—lymphatic system cancer	0.000813	0.00115	CcSEcCtD
Paliperidone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000812	0.00115	CcSEcCtD
Paliperidone—Pain—Bleomycin—lymphatic system cancer	0.000809	0.00114	CcSEcCtD
Paliperidone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000808	0.00114	CcSEcCtD
Paliperidone—Headache—Fludarabine—lymphatic system cancer	0.000808	0.00114	CcSEcCtD
Paliperidone—Tachycardia—Carmustine—lymphatic system cancer	0.000806	0.00114	CcSEcCtD
Paliperidone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000801	0.00113	CcSEcCtD
Paliperidone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000801	0.00113	CcSEcCtD
Paliperidone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000801	0.00113	CcSEcCtD
Paliperidone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000798	0.00113	CcSEcCtD
Paliperidone—Lethargy—Methotrexate—lymphatic system cancer	0.000794	0.00112	CcSEcCtD
Paliperidone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000794	0.00112	CcSEcCtD
Paliperidone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000791	0.00112	CcSEcCtD
Paliperidone—Oedema—Vincristine—lymphatic system cancer	0.000788	0.00111	CcSEcCtD
Paliperidone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000788	0.00111	CcSEcCtD
Paliperidone—Anorexia—Carmustine—lymphatic system cancer	0.000787	0.00111	CcSEcCtD
Paliperidone—Infection—Vincristine—lymphatic system cancer	0.000783	0.00111	CcSEcCtD
Paliperidone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000779	0.0011	CcSEcCtD
Paliperidone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000778	0.0011	CcSEcCtD
Paliperidone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000774	0.00109	CcSEcCtD
Paliperidone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000773	0.00109	CcSEcCtD
Paliperidone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000772	0.00109	CcSEcCtD
Paliperidone—Hypotension—Carmustine—lymphatic system cancer	0.000771	0.00109	CcSEcCtD
Paliperidone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000768	0.00108	CcSEcCtD
Paliperidone—Oedema—Mitoxantrone—lymphatic system cancer	0.000768	0.00108	CcSEcCtD
Paliperidone—Nausea—Fludarabine—lymphatic system cancer	0.000766	0.00108	CcSEcCtD
Paliperidone—Infection—Mitoxantrone—lymphatic system cancer	0.000763	0.00108	CcSEcCtD
Paliperidone—Shock—Mitoxantrone—lymphatic system cancer	0.000755	0.00107	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000752	0.00106	CcSEcCtD
Paliperidone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000752	0.00106	CcSEcCtD
Paliperidone—Urticaria—Bleomycin—lymphatic system cancer	0.000751	0.00106	CcSEcCtD
Paliperidone—Anorexia—Vincristine—lymphatic system cancer	0.000751	0.00106	CcSEcCtD
Paliperidone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000749	0.00106	CcSEcCtD
Paliperidone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000748	0.00106	CcSEcCtD
Paliperidone—Insomnia—Carmustine—lymphatic system cancer	0.000747	0.00106	CcSEcCtD
Paliperidone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000746	0.00105	CcSEcCtD
Paliperidone—Paraesthesia—Carmustine—lymphatic system cancer	0.000741	0.00105	CcSEcCtD
Paliperidone—Hypotension—Vincristine—lymphatic system cancer	0.000736	0.00104	CcSEcCtD
Paliperidone—Dyspnoea—Carmustine—lymphatic system cancer	0.000736	0.00104	CcSEcCtD
Paliperidone—Somnolence—Carmustine—lymphatic system cancer	0.000734	0.00104	CcSEcCtD
Paliperidone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000732	0.00103	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000718	0.00101	CcSEcCtD
Paliperidone—Decreased appetite—Carmustine—lymphatic system cancer	0.000718	0.00101	CcSEcCtD
Paliperidone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000717	0.00101	CcSEcCtD
Paliperidone—Insomnia—Vincristine—lymphatic system cancer	0.000713	0.00101	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000713	0.00101	CcSEcCtD
Paliperidone—Paraesthesia—Vincristine—lymphatic system cancer	0.000708	0.001	CcSEcCtD
Paliperidone—Pain—Carmustine—lymphatic system cancer	0.000706	0.000998	CcSEcCtD
Paliperidone—Constipation—Carmustine—lymphatic system cancer	0.000706	0.000998	CcSEcCtD
Paliperidone—Breast disorder—Methotrexate—lymphatic system cancer	0.000703	0.000994	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000699	0.000988	CcSEcCtD
Paliperidone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000697	0.000985	CcSEcCtD
Paliperidone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000689	0.000974	CcSEcCtD
Paliperidone—Decreased appetite—Vincristine—lymphatic system cancer	0.000685	0.000968	CcSEcCtD
Paliperidone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000684	0.000967	CcSEcCtD
Paliperidone—Somnolence—Mitoxantrone—lymphatic system cancer	0.000682	0.000964	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00068	0.000962	CcSEcCtD
Paliperidone—Feeling abnormal—Carmustine—lymphatic system cancer	0.00068	0.000961	CcSEcCtD
Paliperidone—Fatigue—Vincristine—lymphatic system cancer	0.000679	0.00096	CcSEcCtD
Paliperidone—Asthenia—Bleomycin—lymphatic system cancer	0.000679	0.000959	CcSEcCtD
Paliperidone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000676	0.000955	CcSEcCtD
Paliperidone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000675	0.000954	CcSEcCtD
Paliperidone—Constipation—Vincristine—lymphatic system cancer	0.000674	0.000952	CcSEcCtD
Paliperidone—Pain—Vincristine—lymphatic system cancer	0.000674	0.000952	CcSEcCtD
Paliperidone—Pruritus—Bleomycin—lymphatic system cancer	0.000669	0.000946	CcSEcCtD
Paliperidone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000667	0.000943	CcSEcCtD
Paliperidone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000662	0.000935	CcSEcCtD
Paliperidone—Pancreatitis—Methotrexate—lymphatic system cancer	0.000659	0.000932	CcSEcCtD
Paliperidone—Constipation—Mitoxantrone—lymphatic system cancer	0.000656	0.000928	CcSEcCtD
Paliperidone—Pain—Mitoxantrone—lymphatic system cancer	0.000656	0.000928	CcSEcCtD
Paliperidone—Body temperature increased—Carmustine—lymphatic system cancer	0.000653	0.000922	CcSEcCtD
Paliperidone—Abdominal pain—Carmustine—lymphatic system cancer	0.000653	0.000922	CcSEcCtD
Paliperidone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000645	0.000911	CcSEcCtD
Paliperidone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000644	0.000911	CcSEcCtD
Paliperidone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000632	0.000894	CcSEcCtD
Paliperidone—Dysuria—Methotrexate—lymphatic system cancer	0.000629	0.000889	CcSEcCtD
Paliperidone—Neutropenia—Methotrexate—lymphatic system cancer	0.000629	0.000889	CcSEcCtD
Paliperidone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000628	0.000887	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000625	0.000883	CcSEcCtD
Paliperidone—Abdominal pain—Vincristine—lymphatic system cancer	0.000623	0.00088	CcSEcCtD
Paliperidone—Body temperature increased—Vincristine—lymphatic system cancer	0.000623	0.00088	CcSEcCtD
Paliperidone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000619	0.000875	CcSEcCtD
Paliperidone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00061	0.000862	CcSEcCtD
Paliperidone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000608	0.00086	CcSEcCtD
Paliperidone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000607	0.000857	CcSEcCtD
Paliperidone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000607	0.000857	CcSEcCtD
Paliperidone—Pneumonia—Methotrexate—lymphatic system cancer	0.000603	0.000852	CcSEcCtD
Paliperidone—Vomiting—Bleomycin—lymphatic system cancer	0.000601	0.00085	CcSEcCtD
Paliperidone—Infestation NOS—Methotrexate—lymphatic system cancer	0.0006	0.000847	CcSEcCtD
Paliperidone—Infestation—Methotrexate—lymphatic system cancer	0.0006	0.000847	CcSEcCtD
Paliperidone—Depression—Methotrexate—lymphatic system cancer	0.000598	0.000845	CcSEcCtD
Paliperidone—Rash—Bleomycin—lymphatic system cancer	0.000596	0.000843	CcSEcCtD
Paliperidone—Dermatitis—Bleomycin—lymphatic system cancer	0.000596	0.000842	CcSEcCtD
Paliperidone—Asthenia—Carmustine—lymphatic system cancer	0.000592	0.000837	CcSEcCtD
Paliperidone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000583	0.000824	CcSEcCtD
Paliperidone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000581	0.000821	CcSEcCtD
Paliperidone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000567	0.000801	CcSEcCtD
Paliperidone—Epistaxis—Methotrexate—lymphatic system cancer	0.000566	0.000799	CcSEcCtD
Paliperidone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000565	0.000799	CcSEcCtD
Paliperidone—Asthenia—Vincristine—lymphatic system cancer	0.000565	0.000799	CcSEcCtD
Paliperidone—Diarrhoea—Carmustine—lymphatic system cancer	0.000565	0.000798	CcSEcCtD
Paliperidone—Nausea—Bleomycin—lymphatic system cancer	0.000562	0.000794	CcSEcCtD
Paliperidone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00056	0.000791	CcSEcCtD
Paliperidone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000551	0.000778	CcSEcCtD
Paliperidone—Dizziness—Carmustine—lymphatic system cancer	0.000546	0.000772	CcSEcCtD
Paliperidone—Diarrhoea—Vincristine—lymphatic system cancer	0.000539	0.000762	CcSEcCtD
Paliperidone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000532	0.000751	CcSEcCtD
Paliperidone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000528	0.000746	CcSEcCtD
Paliperidone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000525	0.000742	CcSEcCtD
Paliperidone—Vomiting—Carmustine—lymphatic system cancer	0.000525	0.000742	CcSEcCtD
Paliperidone—Dizziness—Vincristine—lymphatic system cancer	0.000521	0.000736	CcSEcCtD
Paliperidone—Rash—Carmustine—lymphatic system cancer	0.000521	0.000736	CcSEcCtD
Paliperidone—Dermatitis—Carmustine—lymphatic system cancer	0.00052	0.000735	CcSEcCtD
Paliperidone—Headache—Carmustine—lymphatic system cancer	0.000517	0.000731	CcSEcCtD
Paliperidone—Eye disorder—Methotrexate—lymphatic system cancer	0.000503	0.000711	CcSEcCtD
Paliperidone—Tinnitus—Methotrexate—lymphatic system cancer	0.000502	0.000709	CcSEcCtD
Paliperidone—Vomiting—Vincristine—lymphatic system cancer	0.000501	0.000708	CcSEcCtD
Paliperidone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.0005	0.000706	CcSEcCtD
Paliperidone—Rash—Vincristine—lymphatic system cancer	0.000497	0.000702	CcSEcCtD
Paliperidone—Dermatitis—Vincristine—lymphatic system cancer	0.000496	0.000702	CcSEcCtD
Paliperidone—Headache—Vincristine—lymphatic system cancer	0.000494	0.000698	CcSEcCtD
Paliperidone—Nausea—Carmustine—lymphatic system cancer	0.00049	0.000693	CcSEcCtD
Paliperidone—Angiopathy—Methotrexate—lymphatic system cancer	0.000488	0.00069	CcSEcCtD
Paliperidone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000488	0.00069	CcSEcCtD
Paliperidone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000486	0.000687	CcSEcCtD
Paliperidone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000485	0.000686	CcSEcCtD
Paliperidone—Rash—Mitoxantrone—lymphatic system cancer	0.000484	0.000684	CcSEcCtD
Paliperidone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000483	0.000683	CcSEcCtD
Paliperidone—Chills—Methotrexate—lymphatic system cancer	0.000483	0.000682	CcSEcCtD
Paliperidone—Headache—Mitoxantrone—lymphatic system cancer	0.000481	0.000679	CcSEcCtD
Paliperidone—Alopecia—Methotrexate—lymphatic system cancer	0.000476	0.000672	CcSEcCtD
Paliperidone—Mental disorder—Methotrexate—lymphatic system cancer	0.000472	0.000666	CcSEcCtD
Paliperidone—Erythema—Methotrexate—lymphatic system cancer	0.000469	0.000662	CcSEcCtD
Paliperidone—Malnutrition—Methotrexate—lymphatic system cancer	0.000469	0.000662	CcSEcCtD
Paliperidone—Nausea—Vincristine—lymphatic system cancer	0.000468	0.000662	CcSEcCtD
Paliperidone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000459	0.000648	CcSEcCtD
Paliperidone—Nausea—Mitoxantrone—lymphatic system cancer	0.000456	0.000644	CcSEcCtD
Paliperidone—Back pain—Methotrexate—lymphatic system cancer	0.000453	0.00064	CcSEcCtD
Paliperidone—Vision blurred—Methotrexate—lymphatic system cancer	0.000442	0.000624	CcSEcCtD
Paliperidone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000435	0.000614	CcSEcCtD
Paliperidone—Anaemia—Methotrexate—lymphatic system cancer	0.000433	0.000612	CcSEcCtD
Paliperidone—Malaise—Methotrexate—lymphatic system cancer	0.000423	0.000597	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—lymphatic system cancer	0.000421	0.000595	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—lymphatic system cancer	0.000419	0.000593	CcSEcCtD
Paliperidone—Cough—Methotrexate—lymphatic system cancer	0.000409	0.000578	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—lymphatic system cancer	0.000406	0.000574	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—lymphatic system cancer	0.000399	0.000564	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—lymphatic system cancer	0.000399	0.000564	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—lymphatic system cancer	0.000399	0.000564	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000396	0.00056	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—lymphatic system cancer	0.000394	0.000557	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—lymphatic system cancer	0.000386	0.000545	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000382	0.00054	CcSEcCtD
Paliperidone—Infection—Methotrexate—lymphatic system cancer	0.00038	0.000537	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000375	0.00053	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000374	0.000529	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—lymphatic system cancer	0.000371	0.000525	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—lymphatic system cancer	0.000365	0.000515	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—lymphatic system cancer	0.000357	0.000505	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000348	0.000492	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—lymphatic system cancer	0.000346	0.000489	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000343	0.000485	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000341	0.000482	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—lymphatic system cancer	0.00034	0.00048	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000337	0.000476	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000332	0.00047	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00033	0.000467	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—lymphatic system cancer	0.00033	0.000466	CcSEcCtD
Paliperidone—Pain—Methotrexate—lymphatic system cancer	0.000327	0.000462	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000315	0.000445	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000313	0.000442	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—lymphatic system cancer	0.000304	0.000429	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000302	0.000427	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000302	0.000427	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000282	0.000398	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—lymphatic system cancer	0.000274	0.000388	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—lymphatic system cancer	0.000271	0.000382	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000262	0.00037	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—lymphatic system cancer	0.000253	0.000357	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—lymphatic system cancer	0.000243	0.000344	CcSEcCtD
Paliperidone—Rash—Methotrexate—lymphatic system cancer	0.000241	0.000341	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—lymphatic system cancer	0.000241	0.00034	CcSEcCtD
Paliperidone—Headache—Methotrexate—lymphatic system cancer	0.00024	0.000339	CcSEcCtD
Paliperidone—Nausea—Methotrexate—lymphatic system cancer	0.000227	0.000321	CcSEcCtD
